Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251 Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves.
Zymeworks in Focus for Insider Activity: Catalysts Ahead Zymeworks' insider EcoR1 Capital is buying shares ahead of expected catalysts in 2025 that could drive the stock price to multiyear highs.
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone.
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi raised $126.8 million in a Hong Kong IPO.
